drug_type
RELEVANT_DRUG
intervention_type
Antibody-Drug Conjugate
drug_description
A fully humanized IgG1 antibody–drug conjugate targeting B7‑H3 (CD276). Upon binding to B7‑H3 on tumor cells, it is internalized and releases a cytotoxic payload; as an IgG1 it may also mediate Fc‑effector functions. Evaluated as IV 8 mg/kg Q3W monotherapy in mCRPC and other advanced solid tumors.
nci_thesaurus_concept_id
C187121
nci_thesaurus_preferred_term
Anti-B7-H3 Antibody-drug Conjugate HS-20093
nci_thesaurus_definition
An antibody-drug conjugate (ADC) composed of a humanized immunoglobulin (Ig) G1 monoclonal antibody directed against the T-cell checkpoint ligand B7-homologue 3 (B7-H3, CD276) covalently linked to a topoisomerase inhibitor (TOPOi), with potential antineoplastic activity. Upon administration of anti-B7-H3 ADC HS-20093, the anti-B7-H3 monoclonal antibody moiety targets and binds to B7-H3 expressed on tumor cells. Upon binding and internalization, the TOPOi is released, and inhibits DNA topoisomerase activity, thereby inhibiting DNA replication and resulting in cell cycle arrest and tumor cell apoptosis. This inhibits the proliferation of B7-H3-expressing tumor cells. B7-H3, a type I transmembrane protein and a member of the B7 co-stimulatory protein superfamily, is an immunoregulatory protein overexpressed on certain tumor cell types and on various immune cells. It is a negative regulator of the T-cell activation and its overexpression plays a key role in tumor cell invasion and metastasis.
drug_category
ANTIBODY DRUG CONJUGATE
drug_class
Conjugate
drug_delivery_route
Intravenous
drug_mechanism_of_action
Fully human IgG1 ADC targeting B7-H3 (CD276). Upon binding to B7-H3 on tumor cells, the complex is internalized and releases a topoisomerase inhibitor payload that inhibits DNA topoisomerase activity, blocking DNA replication and causing cell-cycle arrest and apoptosis of B7-H3–expressing cells; the IgG1 may also mediate Fc-effector functions (e.g., ADCC/ADCP).
drug_name
HS-20093
nct_id_drug_ref
NCT06001255